Virologist at the University of Auckland
To compute deaths “caused” by vaccine side effects, they used EU data on the number of vaccine doses delivered in the Netherlands and data from that country’s national database for adverse drug reaction reporting, which was more voluminous than registry data from other EU countries.
This week saw the release of a new Accepted Manuscript from Oxford University Press for the Infectious Diseases Society of America [1]. The paper highlights a critical issue associated with an mRNA Covid-19 vaccine similar to the Pfizer vaccine we are using here in NZ.
In a nutshell, it shows that SARS-CoV-2 proteins generated from the vaccine were present in the plasma of vaccine recipients (plasma is the colourless fluid part of blood, lymph, or milk, in which red or white blood cells or fat globules are suspended). These proteins are not supposed to be in the blood.
University of Auckland leads Covid-19 vaccine monitoring for the world with Dr. Helen Petousis-Harris at the helm funded by the usual suspects and beneficiaries.
Voices for Freedom produced a flyer with 8 claims in which vaccinologist Helen Petousis-Harris quickly refuted in a Newsroom article.
Trial results suggesting the AstraZeneca-Oxford vaccine might only offer minimal protection against mild and moderate doses of the Covid-19 “South African” variant “is not the news we were looking for”, a New Zealand vaccinologist says.
A New Zealand health expert says there’s no cause for concern after 29 elderly people died in Norway soon after receiving the Pfizer coronavirus vaccine.
The Norwegian Medicines Agency said in a statement some common reactions to the vaccine may have contributed to their deaths, which was to be expected in frail patients.
A total of 29 people, all aged over 75, died out of more than 42,000 vaccinations in the Scandinavian country.
University of Auckland vaccinologist Helen Petousis-Harris said there’s no indication the two are linked and the virus itself poses a much greater threat to the age bracket.
Too few countries have high functioning pharmacovigilance systems, and far fewer are able to undertake robust signal verification and post-licensure studies on safety.